Hairy Cell Leukemia Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about Hairy Cell Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1Phase 2

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Hairy Cell LeukemiaRecurrent Hairy Cell LeukemiaRefractory Hairy Cell Leukemia
National Cancer Institute (NCI)84 enrolled1 locationNCT06965114
Recruiting
Phase 2

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recurrent Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia Variant
National Cancer Institute (NCI)20 enrolled21 locationsNCT06311227
Recruiting
Phase 2

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center86 enrolled10 locationsNCT06561360
Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL)Hairy Cell Leukemia (HCL)Non-Hodgkins Lymphoma (NHL)+2 more
National Cancer Institute (NCI)1,263 enrolled1 locationNCT01087333
Recruiting
Phase 1

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+4 more
Newave Pharmaceutical Inc60 enrolled4 locationsNCT04775745
Recruiting
Phase 2

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia
M.D. Anderson Cancer Center150 enrolled1 locationNCT00412594
Recruiting
Phase 1

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Hairy Cell LeukemiaHairy Cell Leukemia Variant
National Cancer Institute (NCI)27 enrolled1 locationNCT04815356
Recruiting
Phase 2

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Hairy Cell Leukemia
National Cancer Institute (NCI)45 enrolled1 locationNCT04324112
Recruiting
Phase 2

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Hairy Cell Leukemia
National Cancer Institute (NCI)40 enrolled1 locationNCT04322383
Recruiting
Phase 1

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Mantle Cell LymphomaFollicular LymphomaMarginal Zone Lymphoma+5 more
Stanford University148 enrolled1 locationNCT06340737
Recruiting
Not Applicable

Assessment of Disease Burden in Hairy Cell Leukemia

Hairy Cell Leukemia
IRCCS Azienda Ospedaliero-Universitaria di Bologna45 enrolled1 locationNCT06781515
Recruiting

Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management

Hairy Cell Leukemia (HCL)
IRCCS Azienda Ospedaliero-Universitaria di Bologna50 enrolled3 locationsNCT06774677
Recruiting

Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management

Hairy Cell Leukemia (HCL)
IRCCS Azienda Ospedaliero-Universitaria di Bologna50 enrolled1 locationNCT06764524
Recruiting
Phase 2Phase 3

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Hairy Cell Leukemia
University of Giessen210 enrolled76 locationsNCT02131753